Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dr. Lal PathLabsNSE:LALPATHLAB -0.21%93 Median PS Value is ₹1,663.13 as of Aug. 12, 2026, which is 100% below its 10-year median of 0.96. GuruFocus rates NSE:LALPATHLAB with a GF Score™ of 93/100 and a GF Value™ of ₹1,735.83 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, Dr. Lal PathLabs ranks worse than 72.22% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
As of today (2026-08-12), Dr. Lal PathLabs's share price is ₹1949.90. Dr. Lal PathLabs's Median PS Value is ₹1,663.13. Therefore, Dr. Lal PathLabs's Price to Median PS Value for today is 1.17.
The historical rank and industry rank for Dr. Lal PathLabs's Median PS Value or its related term are showing as below:
NSE:LALPATHLAB'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.83 Med: 0.96 Max: 1.17
Current: 1.17
During the past 13 years, the highest Price to Median PS Value of Dr. Lal PathLabs was 1.17. The lowest was 0.83. And the median was 0.96.
NSE:LALPATHLAB's Price-to-Median-PS-Value is ranked worse than 72.22% of 90
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.87
vs NSE:LALPATHLAB: 1.17
Dr. Lal PathLabs (NSE:LALPATHLAB) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Dr. Lal PathLabs's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1949.90
/
1,663.13
=
1.17
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs Median PS Value Related Terms
Dr. Lal PathLabs Median PS Value Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 9.6238.
Dr. Lal PathLabs's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹172.814.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Median PS Value of ₹1,663.13 as of Aug. 12, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Dr. Lal PathLabs and its competitors. This is 173143% above median its historical median of 0.96. Over the past decade, Dr. Lal PathLabs' Median PS Value has ranged from 0.83 to 1.17. According to the industry distribution chart, Dr. Lal PathLabs ranks #65 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 72.2%.
Is Dr. Lal PathLabs' Median PS Value too high?
Dr. Lal PathLabs' current Median PS Value of ₹1,663.13 is 173143% above median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.83 to a high of 1.17. Based on the distribution chart, Dr. Lal PathLabs ranks #65 out of 90 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Dr. Lal PathLabs has a GF Score™ of 93/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #65 out of 90 companies for Median PS Value. This places Dr. Lal PathLabs in the lower half of its industry. The industry median Median PS Value is 0.87. Historically, Dr. Lal PathLabs' own Median PS Value has ranged from 0.83 to 1.17 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.87, based on 90 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current Median PS Value is ₹1,663.13, which is 173143% above median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,735.83, compared to a current price of ₹1,949.90 — trading 12.3% above its estimated fair value. The current Median PS Value is ₹1,663.13, which is 173143% above median its 10-year median of 0.96. Dr. Lal PathLabs' overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Median PS Value is ₹1,663.13 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,949.90 is trading 12.3% above its estimated GF Value™ of ₹1,735.83.
GuruFocus considers Dr. Lal PathLabs to be Modestly Overvalued.
Key valuation signals for NSE:LALPATHLAB:
Median PS Value: ₹1,663.13 (173143% above median its 10-year median of 0.96)
GF Value™: ₹1,735.83 vs. price of ₹1,949.90 (12.3% above fair value)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
93GF Score
Get the complete analysis for NSE:LALPATHLAB
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
